S. Stewart, C. Hart, and D. Hole, Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study, Heart, vol.86, issue.5, pp.516-521, 2001.
DOI : 10.1136/heart.86.5.516

A. Go, E. Hylek, and K. Phillips, Prevalence of Diagnosed Atrial Fibrillation in Adults, JAMA, vol.285, issue.18, pp.2370-2375, 2001.
DOI : 10.1001/jama.285.18.2370

P. Wolf, R. Abbott, and W. Kannel, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke, vol.22, issue.8, pp.983-991, 1991.
DOI : 10.1161/01.STR.22.8.983

P. Kirchhof, A. Auricchio, and J. Bax, Outcome parameters for trials in atrial fibrillation: executive summary

S. Stewart, C. Hart, and D. Hole, A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study, The American Journal of Medicine, vol.113, issue.5, pp.359-364, 2002.
DOI : 10.1016/S0002-9343(02)01236-6

R. Hart, L. Pearce, and M. Aguilar, Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation, Annals of Internal Medicine, vol.146, issue.12, pp.857-867, 2007.
DOI : 10.7326/0003-4819-146-12-200706190-00007

R. Hart, O. Benavente, and R. Mcbride, Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation, Annals of Internal Medicine, vol.131, issue.7, pp.492-501, 1999.
DOI : 10.7326/0003-4819-131-7-199910050-00003

V. Fuster, L. Ryden, and C. Ds, guidelines for the management of patients with atrial fibrillation, Circulation, vol.114, pp.257-354, 2006.

E. Lau, T. Bungard, and R. Tsuyuki, Stroke Prophylaxis in Institutionalized Elderly Patients with Atrial Fibrillation, Journal of the American Geriatrics Society, vol.159, issue.Sep., pp.428-461, 2004.
DOI : 10.7326/0003-4819-124-11-199606010-00004

R. Nieuwlaat, S. Olsson, and G. Lip, Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation, American Heart Journal, vol.153, issue.6, pp.1006-1018, 2007.
DOI : 10.1016/j.ahj.2007.03.008

A. Waldo, R. Becker, and V. Tapson, Hospitalized Patients With Atrial Fibrillation and a High Risk of Stroke Are Not Being Provided With Adequate Anticoagulation, Journal of the American College of Cardiology, vol.46, issue.9, pp.1729-1765, 2005.
DOI : 10.1016/j.jacc.2005.06.077

B. Gage, A. Waterman, and W. Shannon, Validation of Clinical Classification Schemes for Predicting Stroke, JAMA, vol.285, issue.22, pp.2864-70, 2001.
DOI : 10.1001/jama.285.22.2864

B. Gage, Y. Yan, and P. Milligan, Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF), American Heart Journal, vol.151, issue.3, pp.713-722, 2006.
DOI : 10.1016/j.ahj.2005.04.017

C. Johnson, W. Lim, and B. Workman, People Aged Over 75 in Atrial Fibrillation on Warfarin: The Rate of Major Hemorrhage and Stroke in More Than 500 Patient-Years of Follow-Up, Journal of the American Geriatrics Society, vol.128, issue.4, pp.655-664, 2005.
DOI : 10.7326/0003-4819-128-5-199803010-00012

Y. Miyasaka, M. Barnes, and B. Gersh, Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence, Circulation, vol.114, issue.2, pp.119-125, 2006.
DOI : 10.1161/CIRCULATIONAHA.105.595140

G. Naccarelli, H. Varker, and J. Lin, Increasing Prevalence of Atrial Fibrillation and Flutter in the United States, The American Journal of Cardiology, vol.104, issue.11, pp.1534-1539, 2009.
DOI : 10.1016/j.amjcard.2009.07.022

W. Aronow, C. Ahn, and H. Gutstein, Prevalence of Atrial Fibrillation and Association of Atrial Fibrillation with Prior and New Thromboembolic Stroke in Older Patients, Journal of the American Geriatrics Society, vol.323, issue.5, pp.521-524, 1996.
DOI : 10.1056/NEJM199011293232209

W. Freinberg, J. Blackshear, and A. Laupacis, Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications, Arch Intern Med, vol.155, pp.469-73, 199513.

A. Camm, P. Kirchhof, and Y. Lip, Guidelines for the management of atrial fibrillation

R. Hart, L. Pearce, and R. Mcbride, Factors Associated With Ischemic Stroke During Aspirin Therapy in Atrial Fibrillation : Analysis of 2012 Participants in the SPAF I??III Clinical Trials, Stroke, vol.30, issue.6
DOI : 10.1161/01.STR.30.6.1223

T. Wang, J. Massaro, and D. Levy, A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Stydy

D. Lane and G. Lip, Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients, Thrombosis and Haemostasis, vol.101, pp.802-805, 2009.
DOI : 10.1160/TH09-02-0106

J. Schmitt, G. Duray, and B. Gersh, Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications, European Heart Journal, vol.88, issue.4, pp.1038-1045, 2009.
DOI : 10.1136/heart.88.4.357

G. Lip, Coronary Artery Disease and Ischemic Stroke in Atrial Fibrillation, Chest, vol.132, issue.1, pp.8-10, 2007.
DOI : 10.1378/chest.07-0500

D. Conway and G. Lip, Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project), The American Journal of Cardiology, vol.93, issue.11, pp.1422-1425, 2004.
DOI : 10.1016/j.amjcard.2004.02.047

M. Hughes and G. Lip, Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data, Thrombosis and Haemostasis, vol.99, pp.295-304, 2008.
DOI : 10.1160/TH07-08-0508

N. Kagansky, H. Knobler, and E. Rimon, Safety of anticoagulation therapy in well informed older patients. Arch Inter Med, pp.2044-50, 200411.

. Singer-de, G. Albers, and J. Dalen, Antithrombotic Therapy in Atrial Fibrillation, Chest, vol.126, issue.3, pp.429-56, 2004.
DOI : 10.1378/chest.126.3_suppl.429S

P. Kuijer, B. Hutten, and M. Prins, Prediction of the risk of bleeding during anticoagulation treatment for venous thromboembolism. Arch Inter Med, pp.457-60, 19998.

R. Beyth, L. Quinn, and C. Landefeld, Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin ??????Access the ???Journal Club??? discussion of this paper at http://www.elsevier.com/locate/ajmselect/, The American Journal of Medicine, vol.105, issue.2, pp.91-100, 1998.
DOI : 10.1016/S0002-9343(98)00198-3

C. Kearon, J. Ginsberg, and M. Kovacs, Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism, New England Journal of Medicine, vol.349, issue.7, pp.631-640, 2003.
DOI : 10.1056/NEJMoa035422

D. Somme, A. Corvol, and C. Lazarovici, Clinical usefulness in geriatric patients of combining CHADS2 and HEMORR2HAGES scores to guide antithrombotic prophylaxis in atrial fibrillation, Aging Clinical and Experimental Research, vol.23, issue.4, pp.289-94, 2009.
DOI : 10.1007/s11606-007-0477-9

P. Petersen, G. Boysen, and J. Godtfredsen, Placebocontrolled , randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study, Lancet, vol.1, pp.175-184, 1989.

S. Connolly, A. Laupacis, and M. Gent, Canadian atrial fibrillation anticoaguiation (CAFA) study, Journal of the American College of Cardiology, vol.18, issue.2, pp.349-55, 1991.
DOI : 10.1016/0735-1097(91)90585-W

M. Ezekowitz, S. Bridgers, and K. James, Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation, New England Journal of Medicine, vol.327, issue.20, pp.1406-1418, 1992.
DOI : 10.1056/NEJM199211123272002

H. Diener and A. Lowenthal, Antiplatelet therapy to prevent stroke: risk of brain hemorrhage and efficacy in atrial fibrillation, J Neurol Sci, vol.153, p.112, 1997.

O. Benavente, R. Hart, and P. Koudstaal, Antiplatelet therapy for preventing stroke in patients with nonvalvular atrial fibrillation and no previous history of stroke or transient ischemic attacks The Cochrane Collaboration, Stroke Module of the Cochrane Database ofSystematic Reviews, 1999.

I. Posada and V. Barriales, Alternate-day dosing of aspirin in atrial fibrillation, American Heart Journal, vol.138, issue.1, pp.137-180, 1999.
DOI : 10.1016/S0002-8703(99)70259-0

N. Edvardsson, S. Juul-moller, and R. Omblus, Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation, Journal of Internal Medicine, vol.131, issue.1, pp.95-101, 2003.
DOI : 10.7326/0003-4819-131-7-199910050-00003

A. Gullov, B. Koefoed, and P. Petersen, Fixed Minidose Warfarin and Aspirin Alone and in Combination vs Adjusted-Dose Warfarin for Stroke Prevention in Atrial Fibrillation, Archives of Internal Medicine, vol.158, issue.14, pp.1513-1534, 1998.
DOI : 10.1001/archinte.158.14.1513

B. Hellemons, M. Langenberg, and J. Lodder, Primary prevention of arterial thromboembolism in patients with nonrheumatic atrial fibrillation in general practice (the PATAF study, Cerebrovasc Dis, vol.7, p.11, 1997.

S. Connolly, J. Pogue, and R. Hart, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial, Lancet, vol.367, pp.1903-1912, 2006.

S. Connolly, M. Ezekowitz, and S. Yusuf, Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12, pp.1139-51, 2009.
DOI : 10.1056/NEJMoa0905561

D. Poli, E. Antonucci, and E. Grifoni, Bleeding Risk During Oral Anticoagulation in Atrial Fibrillation Patients Older Than 80 Years, Journal of the American College of Cardiology, vol.54, issue.11, pp.999-1002, 2009.
DOI : 10.1016/j.jacc.2009.05.046

S. Daniel, E. , M. , and Y. Chang, PhD and al. The Net Clinical Benefit of Warfarine Anticoagulation in Atrial Fibrillation, Ann Intern Med, vol.151, pp.297-305, 20091.

J. Mant, F. Hobbs, and K. Fletcher, Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial, The Lancet, vol.370, issue.9586, pp.493-503, 2007.
DOI : 10.1016/S0140-6736(07)61233-1

A. Rash, T. Downes, and R. Portner, A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO), Age and Ageing, vol.36, issue.2, pp.151-157, 2007.
DOI : 10.1093/ageing/afl129

D. Mccrory, D. Matchar, and G. Samsa, Physician Attitudes About Anticoagulation for Nonvalvular Atrial Fibrillation in the Elderly, Archives of Internal Medicine, vol.155, issue.3, pp.277-81, 199513.
DOI : 10.1001/archinte.1995.00430030071008

D. Mccormick, J. Gurwitz, and R. Goldberg, Prevalence and Quality of Warfarin Use for Patients With Atrial Fibrillation in the Long-term Care Setting, Archives of Internal Medicine, vol.161, issue.20, pp.2458-63, 2001.
DOI : 10.1001/archinte.161.20.2458

T. Bungard, W. Ghali, and K. Teo, Why Do Patients With Atrial Fibrillation Not Receive Warfarin?, Archives of Internal Medicine, vol.160, issue.1, pp.41-47, 2000.
DOI : 10.1001/archinte.160.1.41

URL : http://archinte.jamanetwork.com/data/journals/intemed/11955/ira81028.pdf

E. Hylek, D. Antonio, J. Evans-molina, and C. , Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation, Stroke, vol.37, issue.4, pp.1075-80, 2006.
DOI : 10.1161/01.STR.0000209239.71702.ce

M. Tinetti, M. Speechley, and S. Ginter, Risk Factors for Falls among Elderly Persons Living in the Community, New England Journal of Medicine, vol.319, issue.26, pp.1701-1708, 1988.
DOI : 10.1056/NEJM198812293192604

R. Keller and P. Slattum, Strategies for prevention of medication-related falls in the elderly, Consult Pharm, vol.18, pp.248-58, 2003.

F. Rodeghiero, R. Stasi, and T. Gernsheimer, Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group, Blood, vol.113, issue.11, pp.2386-2393, 2009.
DOI : 10.1182/blood-2008-07-162503

R. Pisters, D. Lane, and R. Nieuwlaat, A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey

M. Jones, P. Mcewan, C. Morgan, and J. Peters, Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population, Heart, vol.91, issue.4, pp.472-479, 2005.
DOI : 10.1136/hrt.2004.042465

G. Lip, R. Nieuwlaat, and R. Pisters, Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach, Chest, vol.137, issue.2, pp.263-272, 2010.
DOI : 10.1378/chest.09-1584

F. Hobbs, A. Roalfe, and G. Lip, Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial, BMJ, vol.342, issue.jun23 1, 2011.
DOI : 10.1136/bmj.d3653

S. Ederhy, G. Dufaitre, and L. Boyer, Should all patients with non-valvular atrial fibrillation be anticoagulated?, International Journal of Cardiology, vol.143, issue.1, pp.8-15, 2010.
DOI : 10.1016/j.ijcard.2010.01.004

O. Cesari, Fibrillation atriale: qui anticoaguler? Press med, pp.669-681, 2010.

B. Eriksson, O. Dahl, and L. Ahnfelt, Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I, Journal of Thrombosis and Haemostasis, vol.21, issue.Suppl.
DOI : 10.1080/02841859709172072

B. Eriksson, O. Dahl, and H. Büller, A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial, Journal of Thrombosis and Haemostasis, vol.133, issue.1, pp.103-111, 2005.
DOI : 10.1016/S0049-3848(03)00249-4

B. Eriksson, O. Dahl, and N. Rosencher, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, The Lancet, vol.370, issue.9591, pp.949-956, 2007.
DOI : 10.1016/S0140-6736(07)61445-7

B. Eriksson, O. Dahl, and N. Rosencher, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, Journal of Thrombosis and Haemostasis, vol.5, issue.2, pp.2178-2185, 2007.
DOI : 10.1016/S0140-6736(07)61445-7

R. Committee, J. Ginsberg, B. Davidson, and P. Comp, The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery, J Arthroplasty, vol.24, pp.1-9, 2009.

B. Eriksson, L. Borris, and R. Friedman, Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty, New England Journal of Medicine, vol.358, issue.26, pp.2765-2775, 2008.
DOI : 10.1056/NEJMoa0800374

A. Kakkar, B. Brenner, and O. Dahl, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial, The Lancet, vol.372, issue.9632, pp.31-39, 2008.
DOI : 10.1016/S0140-6736(08)60880-6

M. Lassen, W. Ageno, and L. Borris, Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty, New England Journal of Medicine, vol.358, issue.26, pp.2776-2786, 2008.
DOI : 10.1056/NEJMoa076016

A. Turpie, M. Lassen, and B. Davidson, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial, RECORD 4 Investigators, pp.1673-1680, 2009.
DOI : 10.1016/S0140-6736(09)60734-0

L. Wann, A. Curtis, and T. Craig, 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran), Journal of the American College of Cardiology, vol.57, issue.11, pp.1330-1337, 2011.
DOI : 10.1016/j.jacc.2011.01.010

S. Connolly, J. Eikelboom, and C. Joyner, Apixaban in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.364, issue.9
DOI : 10.1056/NEJMoa1007432